PDE5A and erectile dysfunction: Indeed, sildenafil, a PDE5i originally licensed and used for the management of erectile dysfunction, has been successfully repurposed for the management of both refractory Raynaud’s phenomenon and as first line agent in the clinical management of PAH [20,21], extending quite widely the scope for PDE5 inhibition.